Deliver Your News to the World

Mark & Associates, P.C. Investigating Reports of Serious Tendon Injuries Associated with Cipro, Levaquin and Avelox


WEBWIRE

Firm Offering Free Legal Consultations to Patients Who Suffered Tendonitis and Tendon Ruptures During or After Treatment with Fluoroquinolone Antibiotics

July 30, 2008-Uniondale, NY--- Mark & Associates, P.C., a law firm dedicated to representing victims of medication side effects, is investigating reports of serious tendon injuries including tendon ruptures and tendonitis in patients taking the antibiotics Cipro / Proquin (ciprofloxacin), Levaquin (levofloxacin) and Avelox (moxifloxacin). These drugs are members of the fluoroquinolone class of antibiotics and are prescribed to treat respiratory infections including bronchitis, sinusitis and pneumonia, certain sexually transmitted diseases such as gonorrhea, ear infections, urinary tract infections, tuberculosis, anthrax infection, infectious diarrhea and other infections throughout the body. Cipro, Levaquin and Avelox users who suffered tendon injuries can receive free case evaluations by visiting the following websites: http://www.CiproTendonRupture.com, http://www.LevaquinTendonRupture.com, http://www.AveloxTendonRupture.com and http://www.AntibioticTendonRupture.com.

Free legal consultations are also available to tendon injury victims via the firm’s toll-free number: 1-866-50-RIGHTS (1-866-507-4448).
Mark & Associates, P.C. applauds the FDA’s July 8 decision to request that fluoroquinolone manufacturers include black box warnings on the drug labels informing patients and healthcare professionals about the risk of tendinitis and tendon rupture. However, the firm believes that the agency’s action comes late for hundreds of tendon injury victims who may suffer pain, restricted movement and permanent disability throughout the remainder of their lives. Many tendon injury victims must undergo surgery and years of physical therapy; many will never fully recover from their injuries.

Bayer A.G.’s Cipro gained FDA approval in 1987 and was widely prescribed during the anthrax scares following the September 11, 2001 attacks, despite the drug’s health risks and the availability of safer antibiotics effective at treating anthrax infection. Levaquin, manufactured by Ortho-McNeil-Janssen Pharmaceuticals, Inc., was approved late in 2004. Avelox, developed by Bayer A.G. and marketed by Schering-Plough Corporation, gained FDA approval late in 2005. Bayer continues to tout the safety and effectiveness of Cipro and Avelox, even as new studies confirm the risk of side effects associated with the drugs.

Patients taking fluoroquinolone antibiotics who experience pain, swelling and inflammation associated with tendon injuries in the Achilles (heel), shoulder, hand, knee or other area are urged to seek immediate medical treatment. Tendon ruptures and tendinitis can occur during treatment with a fluoroquinolone antibiotic or up to several months after completing a course of treatment. Tendon injuries can be preceded by pain or may occur suddenly and without warning symptoms. Patients affected by tendon injuries during or following treatment with Cipro, Levaquin or Avelox are encouraged to contact Mark & Associates, P.C. for a free legal consultation. For more information on Mark & Associates, P.C. please visit http://www.YouHaveRights.com.

About Mark & Associates, P.C.
Mark & Associates, P.C. is a leading products liability and personal injury law firm with offices in Boston, Massachusetts and Long Island, New York. The firm aggressively represents victims of defective pharmaceuticals and medical devices, dangerous consumer products, bad faith insurance denials, toxic exposure and serious auto and common carrier accidents.

CONTACT: Mark & Associates, P.C.
Jason Mark, Esq.
1-866-507-4448
info@youhaverights.com



WebWireID71291




 
 antibiotic
 tendon
 tendonitis
 cirpo
 levaquin


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.